Compositions and methods for beta secretase inhibition

Patent metadata

Field	Value
Publication number	US-11458117-B2
Application number	US-201816008219-A
Country	US
Kind code	B2
Filing date	Jun 14, 2018
Priority date	Jun 15, 2017
Publication date	Oct 4, 2022
Grant date	Oct 4, 2022

Abstract

Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of β secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of β secretase mediated disorders.

First claim

We claim:

1. A method of inhibiting the activity of β secretase enzyme, said method comprising step of bringing in to contact mammalian cells with a composition consisting of 10%-15% w/w of oroxylin A, 10%-25% w/w of baicalein and 2%-10% w/w of chrysin, to bring about the effect of inhibiting β secretase activity.

2. A method of inhibiting the expression of β secretase, said method comprising step of bringing in to contact mammalian cells with a composition consisting of 10%-15% w/w of oroxylin A, 10%-25% w/w of baicalein and 2%-10% w/w of chrysin, to bring about the effect of decreasing the expression of β secretase enzyme.

3. A method of reducing β amyloid content, by inhibiting the activity and expression of β secretase, said method comprising step of bringing into contact mammalian cells with a composition consisting of 10%-15% w/w of oroxylin A, 10%-25% w/w of baicalein and 2%-10% w/w of chrysin, to reduce the amount of β amyloid.

Assignees

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Sami Labs Ltd

Inventors

• Majeed Muhammed
• Nagabhushanam Kalyanam

Classifications

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A61K31/352 Primary

  condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K31/658)} · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title